Clinical trial results:
A Phase 2 Open-Label Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Nedosiran in Pediatric Patients from Birth to 11 Years of Age with Primary Hyperoxaluria and Relatively Intact Renal Function

Summary

EudraCT number	2021-001083-16
Trial protocol	DE ES PL IT
Global end of trial date	05 February 2025

Results information

Result version number	v1 (current)
This version publication date	22 August 2025
First version publication date	22 August 2025

Trial information

Trial identification

Sponsor protocol code	DCR-PHXC-203

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05001269
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Sponsor organisation address	Novo Nordisk, Novo Allé, Bagsvaerd, Denmark, 2880
Public contact	Clinical Reporting Office (2834), Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, clinicaltrials@novonordisk.com
Scientific contact	Clinical Reporting Office (2834), Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, clinicaltrials@novonordisk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-002493-PIP01-18
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 May 2025
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	05 February 2025
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Main objective of the study trial is to assess the efficacy of nedosiran in neonates, infants, and children with PH and relatively intact renal function based upon eGFR and serum creatinine

Protection of trial subjects:

This study will be conducted in accordance with the protocol and with the consensus ethical principles derived from international guidelines including the Declaration of Helsinki and CIOMS International Ethical Guidelines (CIOMS VI, 2005); applicable International Conference on Harmonisation (ICH) Good Clinical practices (GCP) guidelines, and applicable laws and regulations, including privacy laws.

With regard to paediatric participants, the ICH Harmonised Tripartite Guideline: Clinical Investigation of Medicinal Products in the Paediatric Population (E11, 20 July 2000) and the European Commission Ethical Considerations for Clinical Trials on Medicinal Products Conducted with Minors (18 September 2017) were considered during the design of the trial, and blood volume minimized where possible.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	22 February 2022
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 5
Country: Number of subjects enrolled	Canada: 1
Country: Number of subjects enrolled	Spain: 1
Country: Number of subjects enrolled	Germany: 4
Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	Japan: 1
Country: Number of subjects enrolled	Lebanon: 9
Country: Number of subjects enrolled	Türkiye: 3
Country: Number of subjects enrolled	United Arab Emirates: 2
Worldwide total number of subjects	27
EEA total number of subjects	5

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	5
Children (2-11 years)	22
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was conducted at 13 sites in 9 countries.

Pre-assignment

Screening details:

This is Phase 2, open-label, single-arm uncontrolled study in paediatric subjects with genetically confirmed primary hyperoxaluria (PH), with relatively intact renal function based upon estimated glomerular filtration rate (eGFR) and serum creatinine. A total of 27 subjects were enrolled in the study and all of them completed the study.

Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Children 0 to <2 years

Arm description:

All subjects that included neonates (0 to less than [<] 2 years) with primary hyperoxaluria (PH) and relatively intact renal function based upon eGFR and serum creatinine, received monthly dose of nedosiran (3.5 milligrams per kilogram [mg/kg], not to exceed 170 milligrams [mg]), subcutaneously from Day 1 though Month 6.

Arm type	Experimental
Investigational medicinal product name	Nedosiran
Investigational medicinal product code	DCR-PHXC
Other name	
Pharmaceutical forms	Sterile concentrate
Routes of administration	Subcutaneous use

Dosage and administration details:

Subject were administered a sterile formulation of drug substance (nedosiran sodium) in water for injection, intended for subcutaneous administration. Total monthly dose (3.5 mg/kg, not to exceed 170 mg) was calculated based upon body weight on Day 1 of the study that remained constant throughout the study.

Arm title	Children 2 to <6 years

Arm description:

All subjects that included infants (2 to <6 years) with PH and relatively intact renal function based upon eGFR and serum creatinine, received monthly dose of nedosiran (3.5 mg/kg, not to exceed 170 mg), subcutaneously from Day 1 though Month 6.

Arm type	Experimental
Investigational medicinal product name	Nedosiran
Investigational medicinal product code	DCR-PHXC
Other name	
Pharmaceutical forms	Sterile concentrate
Routes of administration	Subcutaneous use

Dosage and administration details:

Subject were administered a sterile formulation of drug substance (nedosiran sodium) in water for injection, intended for subcutaneous administration. Total monthly dose (3.5 mg/kg, not to exceed 170 mg) was calculated based upon body weight on Day 1 of the study that remained constant throughout the study.

Arm title	Children 6 to 11 years

Arm description:

All subjects that included children (6 to 11 years) with PH and relatively intact renal function based upon eGFR and serum creatinine, received monthly dose of nedosiran (3.5 mg/kg, not to exceed 170 mg), subcutaneously from Day 1 though Month 6.

Arm type	Experimental
Investigational medicinal product name	Nedosiran
Investigational medicinal product code	DCR-PHXC
Other name	
Pharmaceutical forms	Sterile concentrate
Routes of administration	Subcutaneous use

Dosage and administration details:

Subject were administered a sterile formulation of drug substance (nedosiran sodium) in water for injection, intended for subcutaneous administration. Total monthly dose (3.5 mg/kg, not to exceed 170 mg) was calculated based upon body weight on Day 1 of the study that remained constant throughout the study.

Number of subjects in period 1	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years
Started	5	13	9
Modified Intent-To-Treat (MITT)	3 [1]	9 [2]	8 [3]
Safety	5	13	9
Completed	5	13	9

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: This milestone reports MITT population with 3 subjects reported under 0 to <2 years age group.
[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: This milestone reports MITT population with 9 subjects reported under 2 to <6 years age group.
[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
Justification: This milestone reports MITT population with 3 subjects reported under 6 to 11 years age group.

Baseline characteristics

Reporting groups	
Reporting group title	Children 0 to <2 years
Reporting group description:	
All subjects that included neonates (0 to less than [<] 2 years) with primary hyperoxaluria (PH) and relatively intact renal function based upon eGFR and serum creatinine, received monthly dose of nedosiran (3.5 milligrams per kilogram [mg/kg], not to exceed 170 milligrams [mg]), subcutaneously from Day 1 though Month 6.	
Reporting group title	Children 2 to <6 years
Reporting group description:	
All subjects that included infants (2 to <6 years) with PH and relatively intact renal function based upon eGFR and serum creatinine, received monthly dose of nedosiran (3.5 mg/kg, not to exceed 170 mg), subcutaneously from Day 1 though Month 6.	
Reporting group title	Children 6 to 11 years
Reporting group description:	
All subjects that included children (6 to 11 years) with PH and relatively intact renal function based upon eGFR and serum creatinine, received monthly dose of nedosiran (3.5 mg/kg, not to exceed 170 mg), subcutaneously from Day 1 though Month 6.	

Reporting group values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years
Number of subjects	5	13	9
Age Categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	5	0	0
Children (2-11 years)	0	13	9
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	1.30	3.54	7.78
standard deviation	± 0.529	± 1.198	± 1.093
Gender Categorical			
Units: Subjects			
Female	1	6	4
Male	4	7	5

Reporting group values	Total		
Number of subjects	27		
Age Categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		

Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	5		
Children (2-11 years)	22		
Adolescents (12-17 years)	0		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age Continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Gender Categorical			
Units: Subjects			
Female	11		
Male	16		

End points

End points reporting groups

Reporting group title	Children 0 to <2 years

Reporting group description:

All subjects that included neonates (0 to less than [<] 2 years) with primary hyperoxaluria (PH) and relatively intact renal function based upon eGFR and serum creatinine, received monthly dose of nedosiran (3.5 milligrams per kilogram [mg/kg], not to exceed 170 milligrams [mg]), subcutaneously from Day 1 though Month 6.

Reporting group title	Children 2 to <6 years

Reporting group description:

All subjects that included infants (2 to <6 years) with PH and relatively intact renal function based upon eGFR and serum creatinine, received monthly dose of nedosiran (3.5 mg/kg, not to exceed 170 mg), subcutaneously from Day 1 though Month 6.

Reporting group title	Children 6 to 11 years

Reporting group description:

All subjects that included children (6 to 11 years) with PH and relatively intact renal function based upon eGFR and serum creatinine, received monthly dose of nedosiran (3.5 mg/kg, not to exceed 170 mg), subcutaneously from Day 1 though Month 6.

Primary: Percent change from Baseline to Month 6 in spot urinary oxalate-to-creatinine ratio in PH1, PH2, or PH3 subject subgroups

End point title	Percent change from Baseline to Month 6 in spot urinary oxalate-to-creatinine ratio in PH1, PH2, or PH3 subject subgroups[1]

End point description:

This endpoint reported percent change from baseline to Month 6 in spot urinary oxalate-to-creatinine ratio in paediatric subjects (birth to 11 years of age) with genetically confirmed primary hyperoxaluria type 1 (PH1), primary hyperoxaluria type 2 (PH2), or primary hyperoxaluria type 3 (PH3) subgroups. The MITT Population included all subjects who received at least 1 dose of study intervention and have at least 1 post-baseline spot urinary oxalate to creatinine ratio. Here 'Number of subject analysed' signified 'Overall number of subjects analysed' and 'n' signified 'Number Analysed' that is number of subjects with available data for particular timepoint, for the respective arms; and "99999" signifies that data for these categories were not evaluable as the number of subject for the respective category was 0.

End point type	Primary

End point timeframe:

Baseline (Week 0), Month 6

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical hypotheses confirmatory testing was planned in this study. The endpoint is descriptive in nature.

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: Percent change				
arithmetic mean (standard deviation)				
PH1 (n=3,9,8)	-74.06 (± 13.193)	-68.34 (± 8.574)	-61.44 (± 24.565)	
PH2 (n=0,4,1)	99999 (± 99999)	-17.98 (± 37.847)	-16.10 (± 0)	
PH3 (n=2,0,0)	-41.43 (± 13.633)	99999 (± 99999)	99999 (± 99999)	

Statistical analyses

No statistical analyses for this end point

Primary: Absolute change from Baseline to Month 6 in spot urinary oxalate-to-creatinine ratio in PH1, PH2, or PH3 subject subgroups

End point title	Absolute change from Baseline to Month 6 in spot urinary oxalate-to-creatinine ratio in PH1, PH2, or PH3 subject subgroups[2]

End point description:

This endpoint reported absolute change from baseline to Month 6 in spot urinary oxalate-to-creatinine ratio in paediatric subjects (birth to 11 years of age) with genetically confirmed PH1, PH2, or PH3 subgroups. The MITT Population included all subjects who received at least 1 dose of study intervention and have at least 1 post-baseline spot urinary oxalate to creatinine ratio. Here 'Number of subject analysed' signified 'Overall number of subjects analysed' and 'n' signified 'Number Analysed' that is number of subjects with available data for particular timepoint, for the respective arms; and "99999" signifies that data for these categories were not evaluable as the number of subject for the respective category was 0.

End point type	Primary

End point timeframe:

Baseline (Week 0), Month 6

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical hypotheses confirmatory testing was planned in this study. The endpoint is descriptive in nature.

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: micromole/millimole				
arithmetic mean (standard deviation)				
PH1 (n=3,9,8)	-563.972 (± 378.3308)	-316.344 (± 150.6332)	-189.106 (± 120.5939)	
PH2 (n=0,4,1)	99999 (± 99999)	-64.458 (± 92.5196)	-27.583 (± 0)	
PH3 (n=2,0,0)	-135.283 (± 17.1591)	99999 (± 99999)	99999 (± 99999)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

End point title	Number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

End point description:

This endpoint reported number of incidents of TEAEs and SAEs. An adverse event (AE) is any untoward medical occurrence in a patient or clinical study subject, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, and medical events. An AE will be defined as treatment emergent if they have an onset or worsen in severity after a subject receives the study intervention. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

From baseline (Week 0) up to Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: Events				
TEAEs	37	66	38	
SAEs	1	4	2	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Treatment Emergent Adverse Events and Serious Adverse Events-Nature

End point title	Number of Treatment Emergent Adverse Events and Serious Adverse Events-Nature

End point description:

This endpoint reported nature of TEAEs and SAEs. An AE is any untoward medical occurrence in clinical study subject, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent disability/incapacity, is a congenital anomaly/birth defect, and medical events. An AE is treatment emergent if they have an onset or worsen in severity after a subject receives the study drug. TEAEs are considered as leading to discontinuation if the action taken is marked as "drug withdrawn" on the case report form. TEAEs of special interest include injection site reactions, muscle pain and weakness, and kidney stone events. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

From baseline (Week 0) up to Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: Events				
Treatment Related TEAE	2	7	4	
TEAE Leading to Treatment Interruption	1	0	0	
TEAE Leading to Treatment Discontinuation	0	0	0	
Serious Treatment Related TEAE	0	0	0	
Fatal TEAE	0	0	0	
TEAE of Special Interest	7	8	8	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in 12-lead ECG- RR Interval

End point title	Change from Baseline in 12-lead ECG- RR Interval

End point description:

This endpoint reported change from baseline to Month 6 in RR Interval. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: seconds				
arithmetic mean (standard deviation)	0.1 (± 0.16)	0.0 (± 0.10)	-0.1 (± 0.12)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in 12-lead Electrocardiogram (ECG)- ECG Mean Heart Rate

End point title	Change from Baseline in 12-lead Electrocardiogram (ECG)- ECG Mean Heart Rate

End point description:

This endpoint reported change from baseline to Month 6 in ECG mean heart rate. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: beats/minute				
arithmetic mean (standard deviation)	-11.6 (± 32.34)	-4.2 (± 15.73)	6.2 (± 16.98)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in 12-lead ECG-QTcF Interval, Aggregate

End point title	Change from Baseline in 12-lead ECG-QTcF Interval, Aggregate

End point description:

This endpoint reported change from baseline to Month 6 in aggregate QTcF Interval. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: milliseconds				
arithmetic mean (standard deviation)	21.0 (± 17.68)	4.5 (± 14.88)	1.8 (± 13.29)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in 12-lead ECG-QT Interval, Aggregate

End point title	Change from Baseline in 12-lead ECG-QT Interval, Aggregate

End point description:

This endpoint reported change from baseline to Month 6 in aggregate QT Interval. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: milliseconds				
arithmetic mean (standard deviation)	28.0 (± 30.60)	8.2 (± 20.46)	-6.7 (± 23.69)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in 12-lead ECG-QRS Duration, Aggregate

End point title	Change from Baseline in 12-lead ECG-QRS Duration, Aggregate

End point description:

This endpoint reported change from baseline to Month 6 in aggregate QRS Interval. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: milliseconds				
arithmetic mean (standard deviation)	3.2 (± 5.45)	0.5 (± 6.44)	1.7 (± 3.24)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in 12-lead ECG-PR Interval, Aggregate

End point title	Change from Baseline in 12-lead ECG-PR Interval, Aggregate

End point description:

This endpoint reported change from baseline to Month 6 in aggregate PR Interval. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: milliseconds				
arithmetic mean (standard deviation)	3.6 (± 8.56)	1.8 (± 6.39)	-1.0 (± 8.75)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Subjects with Significant Findings- Physical Examination

End point title	Change from Baseline in Subjects with Significant Findings-Physical Examination

End point description:

This endpoint reported change from baseline to Month 6 in number of subjects with significant findings (physical examination). Change from baseline was calculated using formula: value at current time point – baseline value. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: subjects				
number (not applicable)	0	0	-1	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in vital sign assessment-Body Mass Index

End point title	Change from Baseline in vital sign assessment-Body Mass Index

End point description:

This endpoint reported change from baseline to Month 6 in subject's BMI. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: Kilograms per metre square (kg/m^2)				
arithmetic mean (standard deviation)	-0.668 (± 0.8318)	0.152 (± 0.9265)	0.608 (± 0.9316)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in vital sign assessment-Weight

End point title	Change from Baseline in vital sign assessment-Weight

End point description:

This endpoint reported change from baseline to Month 6 in subject's weights. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: kilograms (kg)				
arithmetic mean (standard deviation)	1.130 (± 0.3033)	1.488 (± 1.2636)	2.411 (± 1.4575)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in vital sign assessment- Height

End point title	Change from Baseline in vital sign assessment- Height

End point description:

This endpoint reported change from baseline to Month 6 in subject's heights. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: centimetres				
arithmetic mean (standard deviation)	6.24 (± 2.220)	4.01 (± 1.237)	2.76 (± 1.548)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in vital sign assessment-Oral Body Temperature

End point title	Change from Baseline in vital sign assessment-Oral Body Temperature

End point description:

This endpoint reported change from baseline to Month 6 in subject's oral body temperature. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: degree celcius (°C)				
arithmetic mean (standard deviation)	0.36 (± 0.555)	-0.01 (± 0.441)	-0.00 (± 0.339)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in vital sign assessment-Respiratory Rate

End point title	Change from Baseline in vital sign assessment-Respiratory Rate

End point description:

This endpoint reported change from baseline to Month 6 in subject's respiratory rate. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: breaths/minute				
arithmetic mean (standard deviation)	-1.4 (± 6.77)	-1.8 (± 4.17)	0.8 (± 2.44)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in vital sign assessment-Heart Rate

End point title	Change from Baseline in vital sign assessment-Heart Rate

End point description:

This endpoint reported change from baseline to Month 6 in subject's heart rate. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: beats/minute				
arithmetic mean (standard deviation)	6.2 (± 14.13)	-1.5 (± 12.52)	4.7 (± 16.96)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Haemoglobin

End point title	Change from Baseline in Haematology assessment: Haemoglobin

End point description:

This endpoint reported change from baseline to Month 6 in subject's haemoglobin. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: Grams per decilitre (g/dL)				
arithmetic mean (standard deviation)	0.575 (± 0.7632)	0.155 (± 0.8092)	0.250 (± 0.7051)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in vital sign assessment-Systolic Blood Pressure and Diastolic Blood Pressure

End point title	Change from Baseline in vital sign assessment-Systolic Blood Pressure and Diastolic Blood Pressure

End point description:

This endpoint reported change from baseline to Month 6 in subject's systolic and diastolic blood pressure. Safety population included all subjects who received at least 1 dose of study intervention.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: Millimetres of Mercury (mmHg)				
arithmetic mean (standard deviation)				
Systolic Blood Pressure	6.8 (± 22.20)	-6.8 (± 17.21)	2.8 (± 7.95)	
Diastolic Blood Pressure	7.6 (± 17.84)	1.1 (± 13.62)	2.8 (± 4.27)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Erythrocytes

End point title	Change from Baseline in Haematology assessment: Erythrocytes

End point description:

This endpoint reported change from baseline to Month 6 in subject's erythrocytes. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: Tera cells per litre (10^12 cells /L)				
arithmetic mean (standard deviation)	0.195 (± 0.3375)	0.173 (± 0.2765)	0.055 (± 0.2076)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Haematocrit

End point title	Change from Baseline in Haematology assessment: Haematocrit

End point description:

This endpoint reported change from baseline to Month 6 in subject's haematocrit. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: Ratio of Haematocrit				
arithmetic mean (standard deviation)	0.01 (± 0.025)	0.01 (± 0.019)	0.00 (± 0.023)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Erythrocytes Mean

Corpuscular Volume

End point title	Change from Baseline in Haematology assessment: Erythrocytes Mean Corpuscular Volume

End point description:

This endpoint reported change from baseline to Month 6 in subject's erythrocytes mean corpuscular volume. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: Femtolitre (fL)				
arithmetic mean (standard deviation)	1.70 (± 3.818)	-1.25 (± 2.393)	-0.05 (± 2.530)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Erythrocytes Mean Corpuscular Haemoglobin

End point title	Change from Baseline in Haematology assessment: Erythrocytes Mean Corpuscular Haemoglobin

End point description:

This endpoint reported change from baseline to Month 6 in subject's erythrocytes mean corpuscular haemoglobin. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: picograms				
arithmetic mean (standard deviation)	0.25 (± 0.624)	-0.48 (± 1.244)	0.18 (± 0.738)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology Assessment: Erythrocytes Mean Corpuscular Haemoglobin Concentration

End point title	Change from Baseline in Haematology Assessment: Erythrocytes Mean Corpuscular Haemoglobin Concentration

End point description:

This endpoint reported change from baseline to Month 6 in subject's erythrocytes mean corpuscular heamoglobin concentration. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: g/dL				
arithmetic mean (standard deviation)	-0.42 (± 1.754)	-0.09 (± 1.691)	0.19 (± 0.783)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Reticulocytes

End point title	Change from Baseline in Haematology assessment: Reticulocytes

End point description:

This endpoint reported change from baseline to Month 6 in subject's reticulocytes. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: Percentage of Reticulocytes				
arithmetic mean (standard deviation)	0.15 (± 0.208)	0.14 (± 0.781)	-0.08 (± 0.443)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Platelets

End point title	Change from Baseline in Haematology assessment: Platelets

End point description:

This endpoint reported change from baseline to Month 6 in subject's platelets. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	7	
Units: Giga cells per litre (10^9 cells /L)				
arithmetic mean (standard deviation)	-1.8 (± 40.87)	-18.6 (± 62.25)	-27.7 (± 102.53)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Leukocytes

End point title	Change from Baseline in Haematology assessment: Leukocytes

End point description:

This endpoint reported change from baseline to Month 6 in subject's leukocytes. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: 10^9 cells /L				
arithmetic mean (standard deviation)	-1.460 (± 2.1985)	0.383 (± 2.3556)	-0.625 (± 2.2732)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Lymphocytes

End point title	Change from Baseline in Haematology assessment: Lymphocytes

End point description:

This endpoint reported change from baseline to Month 6 in subject's lymphocytes. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: 10^9 cells /L				
arithmetic mean (standard deviation)	-1.808 (± 2.3547)	0.429 (± 1.1896)	-0.577 (± 0.9109)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Monocytes

End point title	Change from Baseline in Haematology assessment: Monocytes

End point description:

This endpoint reported change from baseline to Month 6 in subject's monocytes. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: 10^9 cells /L				
arithmetic mean (standard deviation)	-0.013 (± 0.2295)	-0.024 (± 0.1306)	-0.038 (± 0.1288)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Mean Platelet Volume

End point title	Change from Baseline in Haematology assessment: Mean Platelet Volume

End point description:

This endpoint reported change from baseline to Month 6 in subject's mean platelet volume. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	7	
Units: fL				
arithmetic mean (standard deviation)	0.05 (± 0.507)	-0.10 (± 0.610)	0.03 (± 0.553)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Basophils

End point title	Change from Baseline in Haematology assessment: Basophils

End point description:

This endpoint reported change from baseline to Month 6 in subject's basophils. Safety population

included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: 10^9 cells /L				
arithmetic mean (standard deviation)	0.035 (± 0.0545)	-0.008 (± 0.0606)	-0.014 (± 0.0320)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Eosinophils

End point title	Change from Baseline in Haematology assessment: Eosinophils

End point description:

This endpoint reported change from baseline to Month 6 in subject's eosinophils. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: 10^9 cells /L				
arithmetic mean (standard deviation)	0.078 (± 0.1441)	0.029 (± 0.1495)	0.106 (± 0.3064)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Neutrophils

End point title	Change from Baseline in Haematology assessment: Neutrophils

End point description:

This endpoint reported change from baseline to Month 6 in subject's neutrophils. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: 10^9 cells /L				
arithmetic mean (standard deviation)	-0.165 (± 2.1021)	-0.073 (± 1.4642)	-0.106 (± 1.3720)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Eosinophils/Leukocytes

End point title	Change from Baseline in Haematology assessment: Eosinophils/Leukocytes

End point description:

This endpoint reported change from baseline to Month 6 in the ratio of eosinophils/leukocytes. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: Ratio of Eosinophils/Leukocytes				
arithmetic mean (standard deviation)	1.33 (± 1.531)	0.22 (± 1.829)	1.29 (± 3.061)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Monocytes/Leukocytes

End point title	Change from Baseline in Haematology assessment: Monocytes/Leukocytes

End point description:

This endpoint reported change from baseline to Month 6 in the ratio of monocytes/leukocytes. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: Ratio of Lymphocytes/Leukocytes				
arithmetic mean (standard deviation)	0.70 (± 2.534)	-0.45 (± 1.109)	-0.14 (± 1.255)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Lymphocytes/Leukocytes

End point title	Change from Baseline in Haematology assessment: Lymphocytes/Leukocytes

End point description:

This endpoint reported change from baseline to Month 6 in the ratio of lymphocytes/leukocytes. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: Ratio of Lymphocytes/Leukocytes				
arithmetic mean (standard deviation)	-10.25 (± 16.801)	2.20 (± 9.901)	-2.51 (± 13.862)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Neutrophils/Leukocytes

End point title	Change from Baseline in Haematology assessment: Neutrophils/Leukocytes

End point description:

This endpoint reported change from baseline to Month 6 in the ratio of neutrophils/leukocytes. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: Ratio of Neutrophils/Leukocytes				
arithmetic mean (standard deviation)	7.63 (± 14.717)	-2.31 (± 9.655)	1.50 (± 12.398)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Alanine Aminotransferase

End point title	Change from Baseline in Clinical Chemistry Parameter: Alanine Aminotransferase

End point description:

This endpoint reported change from baseline to Month 6 in alanine aminotransferase. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	8	
Units: Units per litre (U/L)				
arithmetic mean (standard deviation)	-1.8 (± 4.44)	14.9 (± 24.68)	5.1 (± 4.61)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Haematology assessment: Basophils/Leukocytes

End point title	Change from Baseline in Haematology assessment: Basophils/Leukocytes

End point description:

This endpoint reported change from baseline to Month 6 in the ratio of basophils/leukocytes. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	11	8	
Units: Ratio of Basophils/Leukocytes				
arithmetic mean (standard deviation)	0.55 (± 0.777)	-0.01 (± 0.517)	-0.09 (± 0.606)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase

End point title	Change from Baseline in Clinical Chemistry Parameter: Aspartate Aminotransferase

End point description:

This endpoint reported change from baseline to Month 6 in aspartate aminotransferase. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of

subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	8	
Units: U/L				
arithmetic mean (standard deviation)	-4.0 (± 11.94)	6.4 (± 13.83)	7.1 (± 6.94)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Lactate Dehydrogenase

End point title	Change from Baseline in Clinical Chemistry Parameter: Lactate Dehydrogenase

End point description:

This endpoint reported change from baseline to Month 6 in lactate dehydrogenase. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	12	7	
Units: U/L				
arithmetic mean (standard deviation)	-29.3 (± 17.29)	19.5 (± 67.20)	1.6 (± 23.44)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Glutamate Dehydrogenase

End point title	Change from Baseline in Clinical Chemistry Parameter:

	Glutamate Dehydrogenase

End point description:

This endpoint reported change from baseline to Month 6 in glutamate dehydrogenase. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	12	8	
Units: U/L				
arithmetic mean (standard deviation)	0.00 (± 0.000)	0.28 (± 0.601)	0.06 (± 0.316)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Gamma Glutamyl Transferase

End point title	Change from Baseline in Clinical Chemistry Parameter: Gamma Glutamyl Transferase

End point description:

This endpoint reported change from baseline to Month 6 in gamma glutamyl transferase. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	8	
Units: U/L				
arithmetic mean (standard deviation)	-0.4 (± 4.45)	1.4 (± 1.89)	1.6 (± 0.92)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Alkaline Phosphatase

End point title	Change from Baseline in Clinical Chemistry Parameter: Alkaline Phosphatase

End point description:

This endpoint reported change from baseline to Month 6 in alkaline phosphatase. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	8	
Units: U/L				
arithmetic mean (standard deviation)	-6.6 (± 19.65)	14.6 (± 37.61)	-8.4 (± 14.88)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Bilirubin and Direct Bilirubin

End point title	Change from Baseline in Clinical Chemistry Parameter: Bilirubin and Direct Bilirubin

End point description:

This endpoint reported change from baseline to Month 6 in bilirubin and direct bilirubin. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subject analysed' signified 'Overall number of subjects analysed' and 'n' signified 'Number Analyzed' that is number of subjects with available data for particular timepoint, for the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	8	
Units: micromole per litre (umol/L)				
arithmetic mean (standard deviation)				
Bilirubin (n=5,13,8)	-0.46 (± 1.389)	1.62 (± 3.467)	1.23 (± 2.355)	
Direct Bilirubin (n=4,12,7)	-0.07 (± 0.096)	0.20 (± 1.224)	-0.03 (± 0.588)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Protein

End point title	Change from Baseline in Clinical Chemistry Parameter: Protein

End point description:

This endpoint reported change from baseline to Month 6 in protein. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	8	
Units: Grams per litre (g/L)				
arithmetic mean (standard deviation)	-0.8 (± 6.76)	0.6 (± 3.71)	-2.0 (± 5.55)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Albumin

End point title	Change from Baseline in Clinical Chemistry Parameter: Albumin

End point description:

This endpoint reported change from baseline to Month 6 in albumin. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: g/L				
arithmetic mean (standard deviation)	-0.2 (± 2.17)	1.2 (± 2.79)	-0.2 (± 2.64)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Creatine Kinase

End point title	Change from Baseline in Clinical Chemistry Parameter: Creatine Kinase

End point description:

This endpoint reported change from baseline to Month 6 in creatine kinase. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	8	
Units: U/L				
arithmetic mean (standard deviation)	-45.6 (± 58.24)	9.5 (± 37.12)	5.0 (± 20.34)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Sodium

End point title	Change from Baseline in Clinical Chemistry Parameter: Sodium

End point description:

This endpoint reported change from baseline to Month 6 in sodium. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: millimole per litre (mmol/L)				
arithmetic mean (standard deviation)	-0.4 (± 2.51)	-0.6 (± 2.79)	-0.2 (± 2.91)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Potassium

End point title	Change from Baseline in Clinical Chemistry Parameter: Potassium

End point description:

This endpoint reported change from baseline to Month 6 in potassium. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	8	
Units: mmol/L				
arithmetic mean (standard deviation)	-0.42 (± 0.356)	-0.11 (± 0.571)	-0.15 (± 0.411)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Chloride

End point title	Change from Baseline in Clinical Chemistry Parameter: Chloride

End point description:

This endpoint reported change from baseline to Month 6 in chloride. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	8	
Units: mmol/L				
arithmetic mean (standard deviation)	-1.0 (± 1.22)	0.4 (± 2.93)	-0.9 (± 2.64)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Creatinine

End point title	Change from Baseline in Clinical Chemistry Parameter: Creatinine

End point description:

This endpoint reported change from baseline to Month 6 in creatinine. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	8	
Units: umol/L				
arithmetic mean (standard deviation)	0.66 (± 5.062)	1.10 (± 6.327)	1.26 (± 1.965)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Plasma Oxalate

End point title	Change from Baseline in Clinical Chemistry Parameter: Plasma Oxalate

End point description:

This endpoint reported change from baseline to Month 6 in plasma oxalate. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subject analysed' signifies 'Overall number of subjects analysed'; 'n' signifies 'Number Analyzed' that is number of subjects with available data for particular timepoint, for the respective arms; and "99999" signifies that

data for these categories were not evaluable as the number of subject for the respective category was 0.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	8	5	
Units: umol/L				
arithmetic mean (standard deviation)				
PH1 (n=3,6,5)	-9.000 (± 10.5830)	-5.667 (± 2.6583)	-4.400 (± 4.3932)	
PH2 (n=0,2,0)	99999 (± 99999)	-2.500 (± 0.7071)	99999 (± 99999)	
PH3 (n=2,0,0)	-2.000 (± 1.4142)	99999 (± 99999)	99999 (± 99999)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Blood Urea Nitrogen

End point title	Change from Baseline in Clinical Chemistry Parameter: Blood Urea Nitrogen

End point description:

This endpoint reported change from baseline to Month 6 in blood urea nitrogen. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	8	
Units: mmol/L				
arithmetic mean (standard deviation)	0.56 (± 2.016)	0.06 (± 1.999)	-0.11 (± 1.082)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Clinical Chemistry Parameter: Cystatin C

End point title	Change from Baseline in Clinical Chemistry Parameter: Cystatin C

End point description:

This endpoint reported change from baseline to Month 6 in cystatin C. Safety population included all subjects who received at least 1 dose of study intervention. Here 'Number of subjects analysed' signified number of subject with available data for particular timepoint, in the respective arms.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	12	9	
Units: milligrams per litre (mg/L)				
arithmetic mean (standard deviation)	-0.120 (± 0.1595)	-0.026 (± 0.1962)	0.024 (± 0.1283)	

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)

End point title	Plasma Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)

End point description:

This endpoint was expected to report Cmax which is defined as maximum observed concentration. However, in this study, a non-compartmental PK analysis was not planned or executed due to the limited PK samples collected in paediatric subjects per protocol, hence these PK parameters were not estimated. The PK population included all subjects who had received at least 1 dose of study intervention (without major dosing violations) and had at least 1 evaluable postdose PK assessment.

End point type	Secondary

End point timeframe:

Day 1: Postdose 0- to 4-hour and 4- to 24-hour, Days 2, 30, and 90: post dose, Day 150: predose and Day 150: postdose: 0- to 4-hour and 4- to 24-hour

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0[3]	0[4]	0[5]	
Units: nanograms per millilitre (ng/mL)				
arithmetic mean (standard deviation)	()	()	()	

Notes:

[3] - Cmax was not estimable due to limited sample collection.

[4] - Cmax was not estimable due to limited sample collection.

[5] - Cmax was not estimable due to limited sample collection.

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma PK Parameters: Area Under the Concentration-time Curve Calculated to the Last Observable concentration at time t (AUCt)

End point title	Plasma PK Parameters: Area Under the Concentration-time Curve Calculated to the Last Observable concentration at time t (AUCt)

End point description:

This endpoint was expected to report AUCt which is defined as area under the concentration-time curve calculated to the last observable concentration at time t. However, in this study, a non-compartmental PK analysis was not planned or executed due to the limited PK samples collected in paediatric subjects per protocol, hence these PK parameters were not estimated. The PK population included all subjects who had received at least 1 dose of study intervention (without major dosing violations) and had at least 1 evaluable postdose PK assessment.

End point type	Secondary

End point timeframe:

Day 1: Postdose 0- to 4-hour and 4- to 24-hour, Days 2, 30, and 90: post dose, Day 150: predose and Day 150: postdose: 0- to 4-hour and 4- to 24-hour

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0[6]	0[7]	0[8]	
Units: hour*nanograms per millilitre				
arithmetic mean (standard deviation)	()	()	()	

Notes:

[6] - AUCt was not estimable due to limited sample collection.

[7] - AUCt was not estimable due to limited sample collection.

[8] - AUCt was not estimable due to limited sample collection.

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma PK Parameters: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞)

End point title	Plasma PK Parameters: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞)

End point description:

This endpoint was expected to report AUC∞ which is defined as area under the concentration-time curve from time zero to infinity. However, in this study, a non-compartmental PK analysis was not planned or executed due to the limited PK samples collected in paediatric subjects per protocol, hence these PK parameters were not estimated. The PK population included all subjects who had received at least 1 dose of study intervention (without major dosing violations) and had at least 1 evaluable postdose PK assessment.

End point type	Secondary

End point timeframe:

Day 1: Postdose 0- to 4-hour and 4- to 24-hour, Days 2, 30, and 90: post dose, Day 150: predose and Day 150: postdose: 0- to 4-hour and 4- to 24-hour

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0[9]	0[10]	0[11]	
Units: hour*nanograms per millilitre				
arithmetic mean (standard deviation)	()	()	()	

Notes:

[9] - AUC∞ was not estimable due to limited sample collection.

[10] - AUC∞ was not estimable due to limited sample collection.

[11] - AUC∞ was not estimable due to limited sample collection.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Spot Urinary Oxalate-to-Creatinine Ratio <=Upper Limit of Normal (ULN) or <=1.5*ULN at any time point through Month 6 in PH1, PH2, or PH3 Subject Subgroups

End point title	Percentage of Subjects with Spot Urinary Oxalate-to-Creatinine Ratio <=Upper Limit of Normal (ULN) or <=1.5*ULN at any time point through Month 6 in PH1, PH2, or PH3 Subject Subgroups

End point description:

This endpoint reported percentage of subjects from baseline to Month 6 Oxalate-to-creatinine Ratio less than and equal to (<=) upper limit of normal (ULN) or <=1.5*ULN at any time point through Month 6 in paediatric subjects (birth to 11 years of age) with genetically confirmed PH1, PH2, or PH3 subgroups. The MITT Population included all subjects who received at least 1 dose of study intervention and have at least 1 post-baseline spot urinary oxalate to creatinine ratio. Here 'Number of subject analysed' signifies 'Overall number of subjects analysed'; 'n' signifies 'Number Analyzed' that is number of subjects with available data for particular timepoint, for the respective arms; and "99999" signifies that data for these categories were not evaluable as the number of subject for the respective category was 0.

End point type	Secondary

End point timeframe:

From baseline (week 0) through Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	13	9	
Units: Percentage of subjects				
number (not applicable)				
PH1: <= 1.0 * ULN (n=3,9,8)	66.7	44.4	62.5	
PH1: <= 1.5 * ULN (n=3,9,8)	100	88.9	100	
PH2: <= 1.0 * ULN (n=0,4,1)	99999	50.0	0	
PH2: <= 1.5 * ULN (n=0,4,1)	99999	75.0	100	

PH3: <= 1.0 * ULN (n=2,0,0)	50.0	99999	99999	
PH3: <= 1.5 * ULN (n=2,0,0)	100	99999	99999	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in eGFR at Month 6 (only in subjects >=12 Months of age at Screening) in PH1, PH2, or PH3 subject subgroups

End point title	Change from Baseline in eGFR at Month 6 (only in subjects >=12 Months of age at Screening) in PH1, PH2, or PH3 subject subgroups

End point description:

This endpoint reported Change from Baseline in GFR estimated Cystatin C at Month 6 (only in subjects >=12 Months of age at Screening) in PH1, PH2, or PH3 subject subgroups. MITT Population included all subjects who received at least 1 dose of study intervention and have at least 1 post-baseline spot urinary oxalate to creatinine ratio. The eGFR was calculated using multivariate Schwartz equation using formula: eGFR=39.8*[ht/Scr]^0.456 [1.8/cysC]^0.418 [30/BUN]^0.0791.076^male[ht/1.4]^0.179 where ht (height) = metres, Scr (serum creatinine) = milligrams per decilitre (mg/dL), cysC (cystatin C) = mg/L, and BUN (blood urea nitrogen) = mg/dL. Here 'Number of subject analysed' signifies 'Overall number of subjects analysed'; 'n' signifies 'Number Analysed' i.e, number of subjects with available data for particular timepoint, for the respective arms; and "99999" signifies that data for these categories were not evaluable as number of subject for respective category was 0.

End point type	Secondary

End point timeframe:

Baseline (Week 0), Month 6

End point values	Children 0 to <2 years	Children 2 to <6 years	Children 6 to 11 years	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	5	12	9	
Units: millilitre/minute/standard surface area				
arithmetic mean (standard deviation)				
PH1: (n=3,8,8)	0.0 (± 17.06)	0.3 (± 10.02)	-0.8 (± 7.21)	
PH2: (n=0,4,1)	99999 (± 99999)	3.5 (± 13.48)	-7.0 (± 0)	
PH3: (n=2,0,0)	15.0 (± 9.90)	99999 (± 99999)	99999 (± 99999)	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline (Week 0) to Month 6

Adverse event reporting additional description:

AE: Any untoward medical occurrence in subject, temporally associated with use of study drug, whether or not considered related to study drug. TEAE: Any AE if they have an onset or worsen in severity after a subject receives the study. Safety population: All subjects who received at least 1 dose of study drug.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	28

Reporting groups

Reporting group title	Children 0 to <2 years

Reporting group description:

All subjects that included neonates (0 to <2 years) with PH and relatively intact renal function based upon eGFR and serum creatinine, received monthly dose of nedosiran (3.5 mg/kg, not to exceed 170 mg), subcutaneously from Day 1 though Month 6.

Reporting group title	Overall

Reporting group description: -

Reporting group title	Children 6 to 11 years

Reporting group description:

All subjects that included children (6 to 11 years) with PH and relatively intact renal function based upon eGFR and serum creatinine, received monthly dose of nedosiran (3.5 mg/kg, not to exceed 170 mg), subcutaneously from Day 1 though Month 6.

Reporting group title	Children 2 to <6 years

Reporting group description:

All subjects that included infants (2 to <6 years) with PH and relatively intact renal function based upon eGFR and serum creatinine, received monthly dose of nedosiran (3.5 mg/kg, not to exceed 170 mg), subcutaneously from Day 1 though Month 6.

Serious adverse events	Children 0 to <2 years	Overall	Children 6 to 11 years
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 5 (20.00%)	5 / 27 (18.52%)	1 / 9 (11.11%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 5 (0.00%)	2 / 27 (7.41%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelocaliectasis			

subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 5 (20.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Children 2 to <6 years		
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 13 (23.08%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pyelocaliectasis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Gastroenteritis			

subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Children 0 to <2 years	Overall	Children 6 to 11 years
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 5 (100.00%)	23 / 27 (85.19%)	7 / 9 (77.78%)
General disorders and administration site conditions			
Injection site pain			
subjects affected / exposed	1 / 5 (20.00%)	5 / 27 (18.52%)	2 / 9 (22.22%)
occurrences (all)	1	6	3
Pyrexia			
subjects affected / exposed	4 / 5 (80.00%)	6 / 27 (22.22%)	2 / 9 (22.22%)
occurrences (all)	4	9	5
Injection site induration			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Reproductive system and breast disorders			
Balanoposthitis			
subjects affected / exposed	1 / 5 (20.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Respiratory, thoracic and mediastinal disorders			
Cough			

subjects affected / exposed	0 / 5 (0.00%)	4 / 27 (14.81%)	0 / 9 (0.00%)
occurrences (all)	0	5	0
Epistaxis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Rhinorrhoea			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Tonsillar hypertrophy			
subjects affected / exposed	1 / 5 (20.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Psychiatric disorders			
Enuresis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Irritability			
subjects affected / exposed	1 / 5 (20.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Tic			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Investigations			
Cystatin C increased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	1 / 9 (11.11%)
occurrences (all)	0	2	2
Alanine aminotransferase increased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Hepatic enzyme increased			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Urinary sediment			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			

Procedural pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Immunisation reaction			
subjects affected / exposed	1 / 5 (20.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Skin laceration			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Headache			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Thrombocytopenia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	1 / 5 (20.00%)	2 / 27 (7.41%)	0 / 9 (0.00%)
occurrences (all)	5	6	0
Diarrhoea			
subjects affected / exposed	1 / 5 (20.00%)	4 / 27 (14.81%)	1 / 9 (11.11%)
occurrences (all)	1	5	1
Constipation			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0

Vomiting			
subjects affected / exposed	2 / 5 (40.00%)	2 / 27 (7.41%)	0 / 9 (0.00%)
occurrences (all)	2	2	0
Odynophagia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Skin and subcutaneous tissue disorders			
Rash vesicular			
subjects affected / exposed	1 / 5 (20.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Rash			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Macule			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Renal and urinary disorders			
Calculus urinary			
subjects affected / exposed	0 / 5 (0.00%)	3 / 27 (11.11%)	2 / 9 (22.22%)
occurrences (all)	0	6	4
Haematuria			
subjects affected / exposed	0 / 5 (0.00%)	2 / 27 (7.41%)	1 / 9 (11.11%)
occurrences (all)	0	2	1
Dysuria			
subjects affected / exposed	0 / 5 (0.00%)	2 / 27 (7.41%)	2 / 9 (22.22%)
occurrences (all)	0	2	2
Renal colic			
subjects affected / exposed	1 / 5 (20.00%)	3 / 27 (11.11%)	2 / 9 (22.22%)
occurrences (all)	1	3	2
Nephrolithiasis			
subjects affected / exposed	2 / 5 (40.00%)	3 / 27 (11.11%)	1 / 9 (11.11%)
occurrences (all)	6	7	1
Glycosuria			

subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Renal disorder			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Urinary incontinence			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	0 / 5 (0.00%)	2 / 27 (7.41%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Flank pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	0 / 5 (0.00%)	2 / 27 (7.41%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Influenza			
subjects affected / exposed	2 / 5 (40.00%)	3 / 27 (11.11%)	0 / 9 (0.00%)
occurrences (all)	2	3	0
Respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	2 / 27 (7.41%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Nasopharyngitis			
subjects affected / exposed	2 / 5 (40.00%)	4 / 27 (14.81%)	0 / 9 (0.00%)
occurrences (all)	4	8	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	3 / 27 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	8	0
Croup infectious			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
COVID-19			

subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection			
subjects affected / exposed	1 / 5 (20.00%)	3 / 27 (11.11%)	1 / 9 (11.11%)
occurrences (all)	1	4	2
Escherichia urinary tract infection			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	1 / 9 (11.11%)
occurrences (all)	0	4	4
Gastroenteritis			
subjects affected / exposed	1 / 5 (20.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	2	2	0
Scarlet fever			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Otitis media acute			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Hepatitis A			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Impetigo			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection pseudomonal			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Tonsillitis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	1 / 9 (11.11%)
occurrences (all)	0	2	2
Metabolism and nutrition disorders			
Iron deficiency			
subjects affected / exposed	1 / 5 (20.00%)	2 / 27 (7.41%)	0 / 9 (0.00%)
occurrences (all)	1	3	0
Obesity			
subjects affected / exposed	0 / 5 (0.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	0	1	0

Vitamin D deficiency			
subjects affected / exposed	1 / 5 (20.00%)	1 / 27 (3.70%)	0 / 9 (0.00%)
occurrences (all)	1	1	0

Non-serious adverse events	Children 2 to <6 years		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 13 (84.62%)		
General disorders and administration site conditions			
Injection site pain			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Pyrexia			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Injection site induration			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Reproductive system and breast disorders			
Balanoposthitis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	4 / 13 (30.77%)		
occurrences (all)	5		
Epistaxis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Rhinorrhoea			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Tonsillar hypertrophy			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			

Enuresis			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Irritability			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Tic			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Investigations			
Cystatin C increased			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Alanine aminotransferase increased			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Hepatic enzyme increased			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Urinary sediment			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			
Procedural pain			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Immunisation reaction			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Skin laceration			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		

Headache subjects affected / exposed occurrences (all)	0 / 13 (0.00%) 0		
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all) Thrombocytopenia subjects affected / exposed occurrences (all)	 0 / 13 (0.00%) 0 1 / 13 (7.69%) 1		
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	 1 / 13 (7.69%) 1		
Gastrointestinal disorders Abdominal pain upper subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all) Constipation subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all) Odynophagia subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all)	 1 / 13 (7.69%) 1 2 / 13 (15.38%) 3 1 / 13 (7.69%) 1 0 / 13 (0.00%) 0 1 / 13 (7.69%) 1 0 / 13 (0.00%) 0		
Skin and subcutaneous tissue disorders Rash vesicular subjects affected / exposed occurrences (all)	 0 / 13 (0.00%) 0		

Rash			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Macule			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Renal and urinary disorders			
Calculus urinary			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Haematuria			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Dysuria			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Renal colic			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Nephrolithiasis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Glycosuria			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Renal disorder			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Urinary incontinence			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Flank pain			

subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Influenza			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Respiratory tract infection			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	2		
Nasopharyngitis			
subjects affected / exposed	2 / 13 (15.38%)		
occurrences (all)	4		
Upper respiratory tract infection			
subjects affected / exposed	3 / 13 (23.08%)		
occurrences (all)	8		
Croup infectious			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
COVID-19			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Escherichia urinary tract infection			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Gastroenteritis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Scarlet fever			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		

Otitis media acute			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Hepatitis A			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Impetigo			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Urinary tract infection pseudomonal			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Tonsillitis			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Iron deficiency			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	2		
Obesity			
subjects affected / exposed	1 / 13 (7.69%)		
occurrences (all)	1		
Vitamin D deficiency			
subjects affected / exposed	0 / 13 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 December 2021	Amendment 1, version 2.0: The 15-Apr-2021 (Original Protocol, version 1.0) version of the protocol was amended to expand the population to include 6- to 11-year-old subjects. Other principal changes included changing the primary objective from safety to efficacy, adding pregnancy and contraception requirements, adding a maximum dose of 170 mg, updating the number of planned subjects from 15 to 25, and clarifying that the efficacy endpoints were presented by PH1, PH2, or PH3 subgroups. 1) Expanded population to include 6- to 11-year-old subjects. 2) Updated the primary endpoint to efficacy based upon spot urinary oxalate-to-creatinine ratio; safety endpoint was moved to secondary. 3) Added a maximum dose of 170 mg. 4) Clarified for subjects >=6 months of age at Screening, the dose was to remain constant throughout the study (i.e., the dose administered on Day 1 will be the dose administered at all following visits regardless of any change in body weight). 5) Updated number of planned subjects from 15 to 25. 6) Clarified that the secondary efficacy endpoint related to normalisation of spot urinary oxalate-to-creatinine ratio includes subjects with spot urinary oxalate-to-creatinine ratio <= the ULN or <=1.5 x ULN at any time point. 7) Clarified that the efficacy endpoints will be presented by PH1, PH2, or PH3 subgroups. 8) Other study related and administrative changes.
01 November 2022	Amendment 2, version 3.0: The 21-Dec-2021 version of the protocol was amended to expand the population to include <2-year-old subjects. 1) Expanded population to include 0- to 2-year-old subjects. 2) Corrected errors in the Schedule of assessment relating to recording of fluid intake. 3) Other administrative updates.
23 February 2023	Amendment 3, version 4.0: 1) Removed the 10 kg minimum body weight from the inclusion criteria. 2) Added text regarding maximum blood volume collection allowed based on body weight and to direct the Investigator to the Laboratory Manual for the blood draw priority list. 3) Updated study duration from 18 to 24 months. 4) Added text to allow for interval weight gain dose adjustments in concomitant therapy regimens. 5) Updated text to clarify the range of 4 to 7 days for reporting of fluid intake. 6) Added additional text denoting differences in response between participants with PH1 and PH2 in study. 7) Added text regarding spot urine collection in infants. 8) Added text to allow for interval weight gain dose adjustments in concomitant therapy regimens. 9) Other administrative updates

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported